. Author manuscript; available in PMC: 2024 Sep 1.

Published in final edited form as: Contemp Clin Trials. 2023 Jul 18;132:107297. doi: 10.1016/j.cct.2023.107297

Table 4.

Power and sample size estimates (white lines reflect previous ROSE trials; pink lines are more conservative effects for which the current trial is powered)

Hypothesis and subgroup	Est. % of overall population	Est. PPD rate in ECAU (%)	Est. PPD rate in ROSE (%)	Required n for 80% power in the subgroup	Required total n given est.% in population	With 20% attrition
1a: CSQ- screen	82%	13	7	784	957	1,196
1a: CSQ- screen	82%	10	5	870	1,061	1,326
1b: CSQ+ screen	18%	30	16	282	1,567	1,959
1b: CSQ+ screen	18%	25	13	334	1,856	2,320
1a: Medicaid-	51%	13	7	784	1,537	1,921
1a: Medicaid-	51%	12	6	712	1,396	1,745
1b: Medicaid+	49%	30	16	282	576	720
1b: Medicaid+	49%	25	13	334	682	853
1a: No past MDE	87%²⁶	6²⁶	3	1496	1,719	2,149
1b: Past MDE	13%²⁶	33²⁶	16	198	1,523	1,904
1c: EPDS- screen	82%	13	7	784	1,089	1,361
1c: EPDS- screen	82%	10	5	870	1,209	1,511
1d: EPDS+ screen	18%	30	16	282	1,567	1,959
1d: EPDS+ screen	18%	25	13	334	1,856	2,320
1e: Whole sample	100%	15	8	650	650	813